PDS Biotechnology (PDSB) Current Leases (2019 - 2026)
PDS Biotechnology's (PDSB) quarterly Current Leases came in at $36167.0 in Q4 2025, down 40.83% YoY from $61119.0 in Q4 2024, and down 18.07% on a QoQ basis from $44142.0 in Q3 2025.
PDS Biotechnology (PDSB) Current Leases (2019 - 2026) Analysis & Trends
PDS Biotechnology (PDSB) has 7 years of Current Leases data on file, last reported at $36167.0 in Q4 2025.
- Quarterly Current Leases fell 40.83% year-over-year to $36167.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $36167.0 (down 40.83% YoY) and the FY2025 annual result came in at $36167.0, down 40.83% from the prior year.
- Current Leases eased to $36167.0 in Q4 2025, from $44142.0 in the prior quarter.
- In the past five years, Current Leases ranged from a high of $335012.0 in Q2 2022 to a low of $36167.0 in Q4 2025.
- A 5-year average of $125498.5 and a median of $59696.0 in 2023 frame the typical range for Current Leases.
- Annual changes were most pronounced in 2022 — Current Leases surged 151.76% — and 2023, when it sank 82.63%.
- Tracing PDSB's Current Leases over 5 years: stood at $258924.0 in 2021, then plunged by 78.14% to $56612.0 in 2022, then declined by 1.44% to $55794.0 in 2023, then gained by 9.54% to $61119.0 in 2024, then tumbled by 40.83% to $36167.0 in 2025.
- The last three Current Leases figures came in at $36167.0 (Q4 2025), $44142.0 (Q3 2025), and $51937.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 45.93 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 6.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | - |
| 10 | PDS Biotechnology | 11.58 Mn | 11.58 Mn | - | 31,696.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 31,696.00 |
| Dec 31, 2025 | 36,167.00 |
| Sep 30, 2025 | 44,142.00 |
| Jun 30, 2025 | 51,937.00 |
| Mar 31, 2025 | 59,556.00 |
| Dec 31, 2024 | 61,119.00 |
| Sep 30, 2024 | 59,742.00 |
| Jun 30, 2024 | 58,396.00 |
| Mar 31, 2024 | 57,081.00 |
| Dec 31, 2023 | 55,794.00 |
| Sep 30, 2023 | 54,537.00 |
| Jun 30, 2023 | 59,650.00 |
| Mar 31, 2023 | 146,980.00 |
| Dec 31, 2022 | 56,612.00 |
| Sep 30, 2022 | 313,976.00 |
| Jun 30, 2022 | 335,012.00 |
| Mar 31, 2022 | 311,311.00 |
| Dec 31, 2021 | 258,924.00 |
| Sep 30, 2021 | 207,717.00 |
| Jun 30, 2021 | 157,663.00 |